(News Bulletin 247) – Degroof Petercam announced on Tuesday that it had lowered its price target on Poxel from 6.4 to 3.5 euros in order to take into account the dilutive effect linked to the implementation of a new line of financing with Irises.
The Belgian investment house underlines that this target, even reduced, still shows an upside potential of around 400%, which makes it say that the market underestimates the potential of Twymeeg, the main drug candidate of biotech.
The Brussels firm, which maintains its buy recommendation on the stock, stresses that its objective is based up to 90% on its forecasts for Twymeeg, which means that its estimates do not take into account any indications in NASH, adrenomyeloneuropathy (AMN) and autosomal dominant polycystic kidney disease (ADPKD).
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
